TY - JOUR
T1 - Syndecan-4 deficiency limits neointimal formation after vascular injury by regulating vascular smooth muscle cell proliferation and vascular progenitor cell mobilization
AU - Ikesue, Masahiro
AU - Matsui, Yutaka
AU - Ohta, Daichi
AU - Danzaki, Keiko
AU - Ito, Koyu
AU - Kanayama, Masashi
AU - Kurotaki, Daisuke
AU - Morimoto, Junko
AU - Kojima, Tetsuhito
AU - Tsutsui, Hiroyuki
AU - Uede, Toshimitsu
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/5
Y1 - 2011/5
N2 - Objective- Syndecan-4 (Syn4) is a heparan sulfate proteoglycan and works as a coreceptor for various growth factors. We examined whether Syn4-/- could be involved in the development of neointimal formation in vivo. Methods and Results- Wild-type (WT) and Syn4-/--deficient (Syn4 -/-) mice were subjected to wire-induced femoral artery injury. Syn4-/- mRNA was upregulated after vascular injury in WT mice. Neointimal formation was attenuated in Syn4-/- mice, concomitantly with the reduction of Ki67-positive vascular smooth muscle cells (VSMCs). Basic-fibroblast growth factor- or platelet-derived growth factor-BB-induced proliferation, extracellular signal-regulated kinase activation, and expression of cyclin D1 and Bcl-2 were impaired in VSMCs from Syn4-/- mice. To examine the role of Syn4-/- in bone marrow (BM)-derived vascular progenitor cells (VPCs) and vascular walls, we generated chimeric mice by replacing the BM cells of WT and Syn4-/- mice with those of WT or Syn4-/- mice. Syn4-/- expressed by both vascular walls and VPCs contributed to the neointimal formation after vascular injury. Although the numbers of VPCs were compatible between WT and Syn4-/- mice, mobilization of VPCs from BM after vascular injury was defective in Syn4 -/- mice. Conclusion- Syn4-/- deficiency limits neointimal formation after vascular injury by regulating VSMC proliferation and VPC mobilization. Therefore, Syn4-/- may be a novel therapeutic target for preventing arterial restenosis after angioplasty.
AB - Objective- Syndecan-4 (Syn4) is a heparan sulfate proteoglycan and works as a coreceptor for various growth factors. We examined whether Syn4-/- could be involved in the development of neointimal formation in vivo. Methods and Results- Wild-type (WT) and Syn4-/--deficient (Syn4 -/-) mice were subjected to wire-induced femoral artery injury. Syn4-/- mRNA was upregulated after vascular injury in WT mice. Neointimal formation was attenuated in Syn4-/- mice, concomitantly with the reduction of Ki67-positive vascular smooth muscle cells (VSMCs). Basic-fibroblast growth factor- or platelet-derived growth factor-BB-induced proliferation, extracellular signal-regulated kinase activation, and expression of cyclin D1 and Bcl-2 were impaired in VSMCs from Syn4-/- mice. To examine the role of Syn4-/- in bone marrow (BM)-derived vascular progenitor cells (VPCs) and vascular walls, we generated chimeric mice by replacing the BM cells of WT and Syn4-/- mice with those of WT or Syn4-/- mice. Syn4-/- expressed by both vascular walls and VPCs contributed to the neointimal formation after vascular injury. Although the numbers of VPCs were compatible between WT and Syn4-/- mice, mobilization of VPCs from BM after vascular injury was defective in Syn4 -/- mice. Conclusion- Syn4-/- deficiency limits neointimal formation after vascular injury by regulating VSMC proliferation and VPC mobilization. Therefore, Syn4-/- may be a novel therapeutic target for preventing arterial restenosis after angioplasty.
KW - growth factors
KW - neointimal hyperplasia
KW - vascular injury
KW - vascular progenitor cells
KW - vascular smooth muscle cells
UR - http://www.scopus.com/inward/record.url?scp=79955635200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955635200&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.110.217703
DO - 10.1161/ATVBAHA.110.217703
M3 - Article
C2 - 21330609
AN - SCOPUS:79955635200
SN - 1079-5642
VL - 31
SP - 1066
EP - 1074
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 5
ER -